POXEL SA (POXEL.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:POXEL - FR0012432516 - Common Stock
POXEL.PA Key Statistics, Chart & Performance
The current stock price of POXEL.PA is 0.254 EUR. In the past month the price increased by 11.4%. In the past year, price increased by 32.98%.
POXEL.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 65.13 | 42.70B | ||
| 1AE.DE | ARGENX SE | 65.41 | 42.89B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.69B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.63B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.72B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.87B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 858.23M | ||
| IVA.PA | INVENTIVA SA | N/A | 782.22M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 19.91 | 663.75M |
Related stock screener links
About POXEL.PA
Company Profile
Poxel SA is a clinical-stage biopharmaceutical company, which engages in the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 6 full-time employees. The company went IPO on 2015-02-06. The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Company Info
POXEL SA
Imm Le Sunway, 259/261 Avenue Jean Jaures
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 6
Phone: 33437372010
POXEL SA / POXEL.PA FAQ
What does POXEL SA do?
Poxel SA is a clinical-stage biopharmaceutical company, which engages in the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 6 full-time employees. The company went IPO on 2015-02-06. The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
What is the current price of POXEL stock?
The current stock price of POXEL.PA is 0.254 EUR. The price increased by 2.01% in the last trading session.
Does POXEL stock pay dividends?
POXEL.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of POXEL stock?
POXEL.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is POXEL SA (POXEL.PA) stock traded?
POXEL.PA stock is listed on the Euronext Paris exchange.
When does POXEL SA (POXEL.PA) report earnings?
POXEL SA (POXEL.PA) will report earnings on 2026-04-20, after the market close.
POXEL.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to POXEL.PA. When comparing the yearly performance of all stocks, POXEL.PA is a bad performer in the overall market: 78.11% of all stocks are doing better.
POXEL.PA Financial Highlights
Over the last trailing twelve months POXEL.PA reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS increased by 64.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -121.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
POXEL.PA Forecast & Estimates
For the next year, analysts expect an EPS growth of -10.48% and a revenue growth -79.58% for POXEL.PA